209 related articles for article (PubMed ID: 22970709)
1. The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?
Ho WL; Wong H; Yau T
Acta Ophthalmol; 2013 Nov; 91(7):604-9. PubMed ID: 22970709
[TBL] [Abstract][Full Text] [Related]
2. Ocular side effects associated with imatinib mesylate and perifosine for gastrointestinal stromal tumor.
Dogan SS; Esmaeli B
Hematol Oncol Clin North Am; 2009 Feb; 23(1):109-14, ix. PubMed ID: 19248974
[TBL] [Abstract][Full Text] [Related]
3. Ophthalmic complications of targeted cancer therapy and recently recognized ophthalmic complications of traditional chemotherapy.
Kheir WJ; Sniegowski MC; El-Sawy T; Li A; Esmaeli B
Surv Ophthalmol; 2014; 59(5):493-502. PubMed ID: 25130892
[TBL] [Abstract][Full Text] [Related]
4. Ocular side-effects associated with imatinib mesylate (Gleevec).
Fraunfelder FW; Solomon J; Druker BJ; Esmaeli B; Kuyl J
J Ocul Pharmacol Ther; 2003 Aug; 19(4):371-5. PubMed ID: 12964961
[TBL] [Abstract][Full Text] [Related]
5. Ocular toxicity of targeted therapies.
Renouf DJ; Velazquez-Martin JP; Simpson R; Siu LL; Bedard PL
J Clin Oncol; 2012 Sep; 30(26):3277-86. PubMed ID: 22649132
[TBL] [Abstract][Full Text] [Related]
6. [Ocular disorders of anticancer drugs--ocular side effects].
Kashiwagi H
Gan To Kagaku Ryoho; 2010 Sep; 37(9):1639-44. PubMed ID: 20841924
[TBL] [Abstract][Full Text] [Related]
7. Ocular complications of cancer therapy: a primer for the ophthalmologist treating cancer patients.
Hazin R; Abuzetun JY; Daoud YJ; Abu-Khalaf MM
Curr Opin Ophthalmol; 2009 Jul; 20(4):308-17. PubMed ID: 19491683
[TBL] [Abstract][Full Text] [Related]
8. Prevention and management of major side effects of targeted agents in breast cancer.
Metzger Filho O; Saini KS; Azim HA; Awada A;
Crit Rev Oncol Hematol; 2012 Dec; 84 Suppl 1():e79-85. PubMed ID: 20817545
[TBL] [Abstract][Full Text] [Related]
9. Optic and otic side effects of molecular targeted therapies.
O'Leary C
Semin Oncol Nurs; 2014 Aug; 30(3):169-74. PubMed ID: 25085028
[TBL] [Abstract][Full Text] [Related]
10. Ulcerative keratitis in gastrointestinal stromal tumor patients treated with perifosine.
Shome D; Trent J; Espandar L; Hatef E; Araujo DM; Song CD; Kim SK; Esmaeli B
Ophthalmology; 2008 Mar; 115(3):483-7. PubMed ID: 18201764
[TBL] [Abstract][Full Text] [Related]
11. Ocular toxicity related to cetuximab monotherapy in patients with colorectal cancer.
Dranko S; Kinney C; Ramanathan RK
Clin Colorectal Cancer; 2006 Sep; 6(3):224-5. PubMed ID: 17026793
[TBL] [Abstract][Full Text] [Related]
12. Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic review.
Huillard O; Bakalian S; Levy C; Desjardins L; Lumbroso-Le Rouic L; Pop S; Sablin MP; Le Tourneau C
Eur J Cancer; 2014 Feb; 50(3):638-48. PubMed ID: 24256808
[TBL] [Abstract][Full Text] [Related]
13. Imatinib mesylate (Gleevec) induced unilateral optic disc edema.
DeLuca C; Shenouda-Awad N; Haskes C; Wrzesinski S
Optom Vis Sci; 2012 Oct; 89(10):e16-22. PubMed ID: 22960614
[TBL] [Abstract][Full Text] [Related]
14. Periorbital oedema and epiphora as ocular side effects of imatinib mesylate (Gleevec).
Esmaeli B; Diba R; Ahmadi MA; Saadati HG; Faustina MM; Shepler TR; Talpaz M; Fraunfelder R; Rios MB; Kantarjian H
Eye (Lond); 2004 Jul; 18(7):760-2. PubMed ID: 14739914
[No Abstract] [Full Text] [Related]
15. Emerging toxicities in the treatment of non-small cell lung cancer: ocular disorders.
Agustoni F; Platania M; Vitali M; Zilembo N; Haspinger E; Sinno V; Gallucci R; de Braud F; Garassino MC
Cancer Treat Rev; 2014 Feb; 40(1):197-203. PubMed ID: 23850197
[TBL] [Abstract][Full Text] [Related]
16. Ocular toxicity and cancer chemotherapy. A review.
al-Tweigeri T; Nabholtz JM; Mackey JR
Cancer; 1996 Oct; 78(7):1359-73. PubMed ID: 8839540
[TBL] [Abstract][Full Text] [Related]
17. [Problems in the current target therapy of malignancies].
Stukov AN; Gershanovich ML; Filov VA; Imianitov EN
Vopr Onkol; 2005; 51(5):607-11. PubMed ID: 16756022
[No Abstract] [Full Text] [Related]
18. Targeted therapy for gastric cancer--current status.
Kulig J; Kołodziejczyk P; Kulig P; Legutko J
J Oncol Pharm Pract; 2013 Mar; 19(1):75-81. PubMed ID: 22711713
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary toxicities of tyrosine kinase inhibitors.
Peerzada MM; Spiro TP; Daw HA
Clin Adv Hematol Oncol; 2011 Nov; 9(11):824-36. PubMed ID: 22252615
[TBL] [Abstract][Full Text] [Related]
20. Reversing resistance to targeted therapy.
Vidal L; Attard G; Kaye S; De Bono J
J Chemother; 2004 Nov; 16 Suppl 4():7-12. PubMed ID: 15688600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
